Testing PRAX-628 for focal or tonic-clonic seizures
Part of Brain & nervous system clinical trials.
This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of focal onset seizures (starting in one part of the brain) or generalized tonic-clonic seizures (involving both sides of the brain).
- You need to have had a recent brain scan (CT or MRI) that showed no ongoing cause for your epilepsy.
- You should be taking 1 to 3 seizure medications, and the doses must have been stable for at least 30 days before the study starts.
- You must have had at least 2 countable focal seizures per month (or 1 generalized tonic-clonic seizure per month) for the last 3 months.
- You cannot have a history of certain serious mental health conditions (like schizophrenia or OCD), active suicidal thoughts, or certain heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests the safety and side effects of Staccato alprazolam for teens and adults (12+) who have certain types of long-lasting seizures. It may help people by offering a specific medicine option aimed at stopping prolonged seizure episodes under close medical study.
This study tests a new medicine called BHV-7000 for adults whose focal seizures (starting in one part of the brain) are not controlled by current treatments. The goal is to see if it can reduce seizures safely.
This Phase 3 trial tests XEN1101 added to your current seizure medicines for people with primary generalized tonic-clonic seizures. It’s for seizures that have not fully stopped even after trying at least two appropriate medicines.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
This study tests whether a new medication called RAP-219 can help adults with focal seizures (seizures that start in one area of the brain) control their seizures better. You would take this medication alongside your current seizure drugs for about 12 weeks.
Hear when a new Focal Onset Seizure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.